Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Ditto, Wilde One. To your question, when it comes to "trials" with the FDA or related public interest agencies at the federal level, "fast" often means several months--sometimes years. But since the test subjects are being drawn from the US military, in this case, the time line to completion may be a lot shorter than that. Getting the product to market after a successful trial could could still be a lengthy process in itself, though, which usually translates into a longer time frame than investors might like for loading if the news is favorable...For whatever it's worth I'm long on this one no matter what, but I'm still looking at it as Vegas or Atlantic City....Because of self-imposed limits with bulletin board stocks I won't lose much, but in time the gains could be colossal...
I wonder what the timeline is for verifying results on something like this? I know they said it should be a quick study but not sure what qualifies as fast in this industry. I know slow means year(s). I feel like the lack of volume is just everyone holding their collecting breath/wallet waiting to hear something positive or negative. I know I’m just stockpiling some reserve funds to throw in if it comes back positive.
no volume and then dead?
Massive sales contracts with industry behemoths combined with attention from large institutional investors are the only factors that can keep market makers and professional shorts from making minced meat of this stock in the short term...
mms not like the news
Halberds Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
8:21 AM ET 4/30/24 | Dow Jones
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation
JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks.
The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation.
Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
To stay updated on the latest developments from Halberd, subscribe by submitting this form. (https://halberdcorporation.com/contact-us/)
For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC
About Halberd Corporation
Halberd Corporation (OTC PINK:HALB), a publicly traded entity on the OTC Market, adh
How about maybe? :)
Not for much longer. I'd say by noon we launch. :)
$HALB Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
https://www.accesswire.com/857948/halberds-patented-ldn-drug-has-begun-pre-pilot-trials-with-military-veterans
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation
JACKSON CENTER, PA / ACCESSWIRE / April 30, 2024 / Halberd Corporation (OTC PINK:HALB) announced a pre-pilot study of its patented LDN+ drug with military volunteers has now begun with limited participants but is currently expected to accelerate rapidly pending successful initial results. This plan includes a wider pilot study demographic of thirty (30) participants, followed by a significantly larger safety study of 150 participants in the coming weeks.
The military has a significant Post Traumatic Stress Disorder (PTSD) and suicide ideation problem and is actively seeking solutions. Halberd's LDN+ drug acts as an antagonist against chemical and alcohol use disorder (AUD) and is uniquely formulated to relieve pain and anxiety associated PTSD and suicidal ideation.
Additional details will be released as the clinical trial progresses. These studies include not only the patented pharmaceutical but 24/7 wearable physiological and psychological monitoring of all participants and the opportunity for each participant to engage in adjunct therapies.
Great News:
Halberd's Patented LDN+ Drug Has Begun Pre-Pilot Trials With Military Veterans
LDN+ Drug Designed to Combat PTSD and Suicidal Ideation
SEVEN YEARS that you've been waiting on this?!?!? I trust that Halberd is a different entity now than the one you originally encountered. I certainly hope so, but Time will tell...It always does...
"I hope I'm still alive!" Same Here
Like 7 years long term. I hope I'm still alive!
You bet! Good luck to everyone here with this company long term...
any development of FDA approved trail!
free shares are nice well done!
As long as I don't use the money I've set aside for my wife's heart transplant to speculate further with Halberd I should be okay...Riding free shares helps considerably as well...
That detects brain trauma, ours alleviates it. :) Perhaps Abbott has already eyeballed our company! :).
Agree. This isn't the old Halberd/Premier Biomedical. They now have proven inventions and funding and when the 'News' hits main stream if you don't already have your shares you will be out of luck.
I don’t believe it’s a scam…. Believe what you want but I’m invested because of their science. Plus, they now have a government contract (CRADA) in play. It’s in its early stages but progress is being made. Is it risky? Of course, but what OTC stock isn’t…
With that being said, when this runs up…. It’s going to run real hard and fast and I’m not going to miss this opportunity!
⤴️
Fool, I don't own any of this, but come back to see poor souls withering away on a company that was proven a scam long ago.
which one you own?
First it was the University of AZ, now its Mizzou. You know you can rent research labs there, and the Pink stock owner calls it a partnership, right? You can get a letter with them telling them you'll provide royalties later, and they'll sign a 'light partnership PR piece' for you, right, you know this right?
Halberd has been operating out of home offices, old ones at that, making fake pumper videos with terrible sets and actors, you've seen these right? I have.
From extra-corporeal blood cleanings, to nasal spray, to probably nuclear dog food this next quarter, they are all over the place. 10 years, and nothing.
SCAM.
If it's a scam, why would the University of Missouri sully its reputation by partnering with Halberd in the first place? And how could William Hartmann secure a CRADA contract for Military Active Duty and Veterans if they didn't have a plausible solution to PTSD or related systemic disorders? If this company was making false claims wouldn't that emerge during the vetting process initiated by the entities who agreed to work with them?
Bye bye fungi and bye bye brain trauma. Hello $$$$$$$$$$$$$$$ :)
"Could be difference between life and death". I wonder if Mr. Hartman means the patient or Halberd Corp?
$HALB Halberd requests a meeting with the CDC to review their successful eradication of all strains of antibiotic-resistant bacteria and fungi in 10 minutes or less vs up to seven days using conventional means. Could be difference between life and death.
9:19 AM · Apr 18, 2024
$HALB Halberd requests a meeting with the CDC to review their successful eradication of all strains of antibiotic-resistant bacteria and fungi in 10 minutes or less vs up to seven days using conventional means. Could be difference between life and death.
— Halberd Corporation (@HalberdC) April 18, 2024
Never, been a scam from day 1.
I've been watching this one for a while now. The thought of having a niche market for their patented nasal mist spray to combat depression is intriguing to say the least. But since this is, after all, a bulletin board stock I refuse to use the money I've set aside for my wife's heart transplant to buy shares of it. Instead, I've used my spare beer money to take out a small position in Halberd to see where it goes. Does anyone have even a vague idea when this all might come together--perhaps by Labor Day? Just curious...
ask=.0092
vol-284,000
Great news today! This sounds like a solid study they’ve put together. If this trial achieves what Halberd has been claiming it’s capable of this is going to be HUGE. Too many possible partnerships to name!
On another note, I remember Hartman releasing a PR back in 2022 or something talking about Extendalife where their extracorporeal therapy can target certain antigens tied directly to the aging process. Remember this? I was thinking maybe Hartman himself has been doing trials with this? He has to be closer to 90 if he went to college in ‘59. Maybe he’s a walking PR for their technology!?
Oscar Wilde I am sure they are working on the extracorporeal treatment at YSU as well. LDN+ and the nasal spray are the low hanging fruit that can be marketed much faster which is why they moved to the forefront. Getting a Government contract of the scope described is huge and should move everything along big time.👍🙏🤗🔥🔥🧨🧨💥💥
(responsible mod: Bill Moynihan)
Halberd Corp. (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements.
Halberd holds the exclusive rights to 4 granted U.S. Patents, no. 9,216,386 no. 8,758,287 and no. 11,186,629, no. 8,865,733
Halberd Corporation is a biotechnology company and with its partners (Dr. Qiang Shawn Chen and his team at Arizona State University; Dr. William Sturrus and his team at Youngstown State University; Dr. Richard Carr and his team at Mississippi State University), is developing an extra-corporeal (out of the body) treatment against PTSD, CTE, Alzheimer's Disease and other virusses and diseases. With the use of antibodies the disease antigens is targeted. Using radiofrequency / laser technology the "antibody-metallic moiety-antigens complex" is destroyed/eradicated. All based on 4 granted patents and 22 pending provisional/non-provisional (some PCT) patent applications.
2024: In close cooperation with partner (revenue sharing agreement in place) AthenaGTX, Halberd Corp is working on contracts from the military, to develop treatments to tackle Traumatic Brain Injury/TBI (patent pending nasal spray) and Post Traumatic Stress Syndrome/PTSD (patented Low-Dose-Naltrexone product).
CEO William Hartman: "The principal competitive Alzheimer's drug treatment available today eliminates 5-15% of Beta Amyloid after one month of treatment costing over $50,000 per year. Halberd's extracorporeal process eradicates 100% within just 10 minutes."
JACKSON CENTER, PA / ACCESSWIRE / March 14, 2023 / Halberd Corporation (OTC PINK:HALB) is scheduled to meet with Center of Disease Control (CDC) representatives to discuss Halberd's incredible success in eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and Candida auris samples previously provided by the CDC.
JACKSON CENTER, PA / ACCESSWIRE / September 6, 2023 / Halberd Corporation's (OTC PINK:HALB) research at Mississippi State University (MSU) has shown significant reduction in two key markers of traumatic brain injury (TBI) in early testing of Halberd's patent-pending nasal spray to mitigate the effects of TBI. Anecdotal data in preliminary testing reveals a 20% reduction in Neuron Specific Enolase and a 50% reduction in the levels of Glial Fibrillary Acid Protein compared to the control group.
JACKSON CENTER, PA / ACCESSWIRE / September 20, 2023 / Halberd Corporation (OTC PINK:HALB) and Athena GTX, Inc, of Johnston, Iowa commenced collaboration on critical development of submissions for government contracts seeking proposals for the detection and treatment of traumatic brain injury (TBI). The initial focus will be on accelerating and fine-tuning Halberd's proprietary nasal spray for suppressing the effects of traumatic brain injury (TBI).
JACKSON CENTER, PA / ACCESSWIRE / December 13, 2023 / Halberd Corporation (OTC PINK:HALB) and CrodenHealth.com of Canada agree to produce, market, sell and distribute Halberd's patented low dose naltrexone combo product(s) worldwide. The agreement also allows CrodenHealth.com right of first refusal regarding similar rights to future products in Halberd's development pipeline.
JACKSON CENTER, PA / ACCESSWIRE / January 10, 2024 / Halberd Corporation (OTC-PINK:HALB) is thrilled to declare the formalization of a profitable revenue-sharing accord with Athena GTX, Inc., of Johnston, Iowa, (www.athenagtx.com). Athena GTX is a private enterprise specializing in providing medical care solutions tailored for first responders in both civilian and government sectors.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |